Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis

European Journal of Clinical Pharmacology

Volumn 53, Issue 3-4, 1997, Pages 221-228

  Meineke, I ^a   Feltkamp, H ^b   Hogemann A ^b   Gundert Remy, U ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG REEXPOSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRODRUGS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031461066     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050366     Document Type: Article

References (18)

1. Mizno K, Niimura S, Tani M, Saito J, Sanada H, Takakashi M, Okazaki K, Yamaguchi M, Fukuchi S (1992) Hypotensive activity of TV-116, a newly developed angiotensin II receptor antagonist in spontaneously hypertensive rats. Life Sci 51: 183-187
2. Inada Y, Wada T, Shibouta Y, Oijma M, Sanada T, Oktsuki K, Itoh K, Kubo K, Kohara Y, Naka T, Nishikawa K (1994) Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1-receptor antagonist(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116) in various hypertensive rats. J Pharm Exp Ther 268: 1540-1547
3. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner H (1995) Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21
4. Lee JW, Naidong W, Johnson T, Dzerk A, Miyabayashi T, Motohashi M (1995) Development and validation of column-switching high-performance chromatographic methods for the determination of a potent All receptor antagonist, TCV-116, and its metabolites in human serum and urine. J Chromatogr 670: 287-298
5. NONMEM Project Group (1992) In: Beal SL, Sheiner LB (eds) NONMEM users guides. University of California at San Francisco, San Francisco
6. NONMEM Project Group (1992) In: Beal SL, Sheiner LB (eds) In: NONMEM users guides, guide VI. University of California at San Francisco, San Francisco
7. Grasela TH, Sheiner LB (1984) Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 9: 545-554
8. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE (1994) Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 56: 169-175
9. Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429-453
10. Unadkat J, Bartha F, Sheiner LB (1986) Simultaneous modelling of pharmacokinetics and pharmacodynamics with non-parametric kinetic and dynamic models. Clin Pharmacol Ther 40: 86-93
11. Bauer JH, Reams GP (1995) The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med 155: 1361-1368
12. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic response. J Pharmacokinet Biopharm 21: 457-478
13. Karlsson MO, Sheiner LB (1993) The importance of modelling interoccasion variability in pharmacokinetic population analysis. J Pharmacokinet Biopharm 21: 735-750
14. Wade JR, Kelman AW, Howie CA, Whiting B (1993) Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 21: 209-222
15. Wada T, Inada Y, Sanada T, Ojima M, Shibouta Y, Noda M, Nishikawa K (1994) Effects of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Pharmacol 253: 27-34
16. Flesch M, Ko Y, Seul C, Dusing R, Feltkamp H, Vetter H, Sachinidis A (1995) Effects of TCV-116 and CV-11974 on angiotensin induced responses in vascular smooth muscle cells. Eur J Pharmacol 289: 399-402
17. Kim S, Okta K, Hamaguchi A, Omura T, Yukimura T, Miusa K, Inada Y, Ishimura Y, Chatani F, Iwao H (1995) Angiotensin II type receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissue of hypertensive rats. J Pharmacol Exp Ther 273: 509-515
18. Ogihara T, Nagano M, Mikami H, Higaki J, Kohara K, Azuma J, Aoki T, Hamanaka Y (1994) Effects of angiotensin receptor antagonist, TCV 116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 16: 74-96